Anti‐inflammatory and immunomodulatory effects of Lactobacillus spp. as a preservative and therapeutic agent for IBD control

Abstract

Abstract Background Probiotics have a beneficial effect on inflammatory responses and immune regulation, via Janus kinase/signal transduction and activator of transcription (JAK/STAT) and NF‐κB signaling pathways. To evaluate the precise effects of Lactobacillus spp. as a protective and therapeutic agent, we aimed to investigate the efficacy of Lactobacillus spp. in modulating JAK/STAT and nuclear factor kappa B (NF‐κB) inflammatory signaling pathways. Methods A quantitative real‐time polymerase chain reaction (qPCR) assay was used to analyze the expression of JAK/STAT and inflammatory genes (TIR‑associated Protein [TIRAP], Interleukin 1 Receptor Associated Kinase[IRAK4], Nuclear factor‐kappa B Essential Modulator [NEMO], and receptor interacting protein [RIP]) followed by treatment of the HT‐29 cell line with sonicated pathogens before, after, and simultaneously with Lactobacillus spp. A cytokine assay was also used to evaluate interleukin (IL)‐6 and IL‐1β production after treatment with Lactobacillus spp. Results Lactobacillus spp. downregulated JAK and TIRAP, IRAK4, NEMO, and RIP genes in the NF‐κB pathway compared to sonicate‐treated cells. The expression of STAT genes was different after treatment with probiotics. The production of IL‐6 and IL‐1β decreased after probiotic treatment. Conclusions Our Lactobacillus spp. cocktail showed anti‐inflammatory effects on HT‐29 cells by modulating JAK/STAT and NF‐κB signaling pathways in all three treatment variants. Therefore, Lactobacillus spp. as a dietary supplement can both prevent and reduce inflammation‐related diseases such as inflammatory bowel disease.

Keywords

• IBD
• JAK/STAT
• Lactobacillus spp.
• NF‐κB